Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Biomaterials|March 8, 2013
The delivery of thrombi-specific nanoparticles incorporating oligonucleotides into injured cerebrovascular endotheliumWei Shi, Heng Mei, Jun Deng, et al.
Frontiers in Immunology|March 27, 2025
Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2Min Zhang, Yingying Wu, Zhipeng Cheng, et al.
Science Advances|February 6, 2021
A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targetingYanmei He, Lei Lei, Jun Cao, et al.
Clinical and Experimental Medicine|November 5, 2023
Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysisRuowen Wei, Yingying Wu, Shan Jiang, et al.
Annals of Hematology|March 25, 2024
The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset: A nationally representative, prospective, multicentre, observational studyHaixia Fu, Xuan Cai, Lijuan Cui, et al.
Biomaterials|February 12, 2014
Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticlesBo Zhang, Shun Shen, Ziwei Liao, et al.
British Journal of Haematology|September 16, 2021
A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patientsHeng Mei, Min Xu, Guolin Yuan, et al.
Plos Computational Biology|September 1, 2023
Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patientsZhengqing Zhou, Dianjie Li, Ziheng Zhao, et al.
Biomaterials|February 18, 2014
EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain gliomaBo Zhang, Huafang Wang, Ziwei Liao, et al.
Cancer Medicine|October 22, 2025
BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical TrialWenjing Luo, Yinqiang Zhang, Chenggong Li, et al.
Pageof 19